Parexel buying back $150M in stock; ACT Oncology teams with Actinium on cancer R&D;

> Parexel International ($PRXL) has signed a deal with Goldman Sachs to repurchase $150 million of its own stock. More

> CRO ACT Oncology partnered with biotech Actinium Pharmaceuticals to help develop its cancer immunotherapies. News

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.